Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Egypt / NCT07604194
Recruiting Not applicable

Embolosclerotherapy Versus Deep Dorsal Vein Revascularization in Venogenic Erectile Dysfunction

NCT07604194 · tracked via the Priya Life Science Egypt tracker
Sponsor
Mansoura University Hospital
Phase
Not applicable
Started
2026-06-20
Last updated
2026-10-16

Condition(s) studied

Erectile Dysfunction Due to Venous DisorderErectile Dysfunction (ED)

Investigational drug(s) / intervention(s)

Endovascular embolosclerotherapyRevacularization of deep dorsal vein

Endovascular embolosclerotherapy: The goal of endovascular therapy is to achieve adequate embolization of efferent pelvic veins, including the periprostatic and internal or external pudendal veins.

Revacularization of deep dorsal vein: Penile venous arterialization of the Deep Dorsal vein using inferior epigastric artery

Study summary

Venous leakage is one of the causes of erectile dysfunction and can be managed using different treatment modalities, including surgical ligation and percutaneous embolization. This randomized clinical trial aims to evaluate and compare the efficacy, durability, safety, side effects, and complications of two treatment procedures-embolosclerotherapy of the periprostatic plexus and deep dorsal vein revascularization-in the management of erectile dysfunction caused by venous leak.

Eligibility

Sex
MALE
Min age
40 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: * Cases with ED reporting difficulty in attaining or maintaining erection for at least 6 months. * All participants were sexually active, in a stable and heterosexual partnership, living with their sexual partner for at least the past one year, and have only one sexual partner. * The frequency of trying sexual intercourse was ≥1/week. * Unsatisfactory response to PDE5i medication. * All cases suffered venogenic erectile dysfunction diagnosed by color flow Doppler sonography before and after intracavernous injection of vasoactive drugs or Dynamic infusion cavernosometry-cavernosography (selected cases), which indicated veno-occlusive dysfunction. Exclusion Criteria: * Refusal to participate. * Major psychological or psychiatric disorders. * Non-vascular causes of ED including penile anatomic defects, any related neurological etiology or spinal cord injury, hypogonadism and hormonal disturbances. * History of previous venous surgery, suspected or proven deep venous thrombosis, history of Deep Vein Thrombosis.

Primary outcome measure(s)

  • improvement in International Index of Erectile Function — 6 weeks
    minimal clinically important difference, defined as a ≥4-point increase in the EF domain of the IIEF score

Trial sites (1)

FacilityCityRegionStatus
Mansoura University hospital Al Mansurah Dakahlia Governorate Recruiting

More Mansoura University Hospital trials in Egypt

Demographics of Lung Cancer in Females Recruiting
Diaphragmatic Thickening Fraction as a Predictor of Successful Weaning Recruiting
Bronchoscopic Lung Volume Reduction in Management of Localized Emphysema Recruiting
Comparison Between 2 Treatment Modalities of Trigger Finger: Ultrasound-guided Percutaneous Release of A1 Pulley by a Needle Knife Versus Ultrasound-guided Corticosteroid Injection in the Treatment of Trigger Finger Active, not recruiting
Slide Tracheoplasty Versus Tracheal Resection Anastomosis in Acquired Tracheal Stenosis Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07604194 on ClinicalTrials.gov ↗ ← All trials in Egypt